Institute of Chemical Technology Mumbai, Marathwada Campus, Jalna, BT-6/7, Biotechnology Park, Additional MIDC Area, Aurangabad Road, Jalna, Maharashtra, 43120, India.
Department of Biological Sciences and Bioengineering, Indian Institute of Technology Kanpur, Kanpur, Uttar Pradesh, 208016, India.
Biotechnol J. 2021 Feb;16(2):e2000288. doi: 10.1002/biot.202000288. Epub 2020 Sep 28.
High-throughput systems allow screening and analysis of large number of samples simultaneously under same conditions. Over recent years, high-throughput systems have found applications in fields other than drug discovery like bioprocess industries, pollutant detection, material microarrays, etc. With the introduction of materials in such HT platforms, the screening system has been enabled for solid phases apart from conventional solution phase. The use of biomaterials has further facilitated cell-based assays in such platforms. Here, the authors have focused on the recent developments in biomaterial-based platforms including the fabricationusing contact and non-contact methods and utilization of such platforms for discovery of novel biomaterials exploiting interaction of biological entities with surface and bulk properties. Finally, the authors have elaborated on the application of the biomaterial-based high-throughput platforms in tissue engineering and regenerative medicine, cancer and stem cell studies. The studies show encouraging applications of biomaterial microarrays. However, success in clinical applicability still seems to be a far off task majorly due to absence of robust characterization and analysis techniques. Extensive focus is required for developing personalized medicine, analytical tools and storage/shelf-life of cell laden microarrays.
高通量系统允许在相同条件下同时筛选和分析大量样本。近年来,高通量系统已在药物发现等领域之外得到应用,如生物工艺行业、污染物检测、材料微阵列等。随着这些 HT 平台中材料的引入,筛选系统已能够用于除传统溶液相之外的固相。生物材料的使用进一步促进了这些平台中基于细胞的测定。在这里,作者重点介绍了基于生物材料的平台的最新进展,包括使用接触和非接触方法进行制造,以及利用这些平台发现利用生物实体与表面和体相特性相互作用的新型生物材料。最后,作者详细介绍了基于生物材料的高通量平台在组织工程和再生医学、癌症和干细胞研究中的应用。研究表明,生物材料微阵列具有令人鼓舞的应用前景。然而,由于缺乏强大的表征和分析技术,临床应用的成功似乎仍然遥不可及。需要广泛关注开发个性化药物、分析工具以及细胞负载微阵列的储存/保质期。